Skip to main content
Erschienen in: Cancer Chemotherapy and Pharmacology 6/2006

01.12.2006 | Original Article

Screening of an annotated compound library for drug activity in a resistant myeloma cell line

verfasst von: Linda Rickardson, Mårten Fryknäs, Caroline Haglund, Henrik Lövborg, Peter Nygren, Mats G. Gustafsson, Anders Isaksson, Rolf Larsson

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 6/2006

Einloggen, um Zugang zu erhalten

Abstract

Purpose: Resistance to anticancer drugs is a major problem in chemotherapy. In order to identify drugs with selective cytotoxic activity in drug-resistant cancer cells, the annotated compound library LOPAC1280, containing compounds from 56 pharmacological classes, was screened in the myeloma cell line RPMI 8226 and its doxorubicin-resistant subline 8226/Dox40. Methods: Cell survival was measured by the Fluorometric Microculture Cytotoxicity Assay. Results: Selective cytotoxic activity in 8226/Dox40 was obtained for 33 compounds, with the most pronounced difference observed for the glucocorticoids. A microarray analysis of the cells showed a difference in mRNA-expression for the glucocorticoid receptor suggesting potential mechanisms for the difference in glucocorticoid sensitivity. In the presence of the glucocorticoid-receptor antagonist RU486, the sensitivity to the glucocorticoids was reduced and a similar effect level in RPMI 8226 and 8226/Dox40 was achieved. Conclusion: In conclusion, screening of mechanistically annotated compounds on drug-resistant cancer cells can identify compounds with selective activity and provide a basis for the development of novel treatments of drug-resistant malignancies.
Literatur
1.
Zurück zum Zitat Chauhan D, Auclair D, Robinson EK, Hideshima T, Li G, Podar K, Gupta D, Richardson P, Schlossman RL, Krett N, Chen LB, Munshi NC, Anderson KC (2002) Identification of genes regulated by dexamethasone in multiple myeloma cells using oligonucleotide arrays. Oncogene 21:1346–1358CrossRefPubMed Chauhan D, Auclair D, Robinson EK, Hideshima T, Li G, Podar K, Gupta D, Richardson P, Schlossman RL, Krett N, Chen LB, Munshi NC, Anderson KC (2002) Identification of genes regulated by dexamethasone in multiple myeloma cells using oligonucleotide arrays. Oncogene 21:1346–1358CrossRefPubMed
2.
Zurück zum Zitat Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AM, Deeley RG (1992) Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258:1650–1654PubMedCrossRef Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AM, Deeley RG (1992) Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258:1650–1654PubMedCrossRef
3.
Zurück zum Zitat Dalton WS, Durie BG, Alberts DS, Gerlach JH, Cress AE (1986) Characterization of a new drug-resistant human myeloma cell line that expresses P-glycoprotein. Cancer Res 46:5125–5130PubMed Dalton WS, Durie BG, Alberts DS, Gerlach JH, Cress AE (1986) Characterization of a new drug-resistant human myeloma cell line that expresses P-glycoprotein. Cancer Res 46:5125–5130PubMed
4.
Zurück zum Zitat Danel-Moore L, Bronnegard M, Gustafsson JA (1992) Dexamethasone reverses glucocorticoid receptor RNA depression in multi-drug resistant (MDR) myeloma cell lines. Med Oncol Tumor Pharmacother 9:199–204PubMed Danel-Moore L, Bronnegard M, Gustafsson JA (1992) Dexamethasone reverses glucocorticoid receptor RNA depression in multi-drug resistant (MDR) myeloma cell lines. Med Oncol Tumor Pharmacother 9:199–204PubMed
5.
Zurück zum Zitat Danks MK, Yalowich JC, Beck WT (1987) Atypical multiple drug resistance in a human leukemic cell line selected for resistance to teniposide (VM-26). Cancer Res 47:1297–1301PubMed Danks MK, Yalowich JC, Beck WT (1987) Atypical multiple drug resistance in a human leukemic cell line selected for resistance to teniposide (VM-26). Cancer Res 47:1297–1301PubMed
6.
Zurück zum Zitat Danks MK, Schmidt CA, Cirtain MC, Suttle DP, Beck WT (1988) Altered catalytic activity of and DNA cleavage by DNA topoisomerase II from human leukemic cells selected for resistance to VM-26. Biochemistry 27:8861–8869CrossRefPubMed Danks MK, Schmidt CA, Cirtain MC, Suttle DP, Beck WT (1988) Altered catalytic activity of and DNA cleavage by DNA topoisomerase II from human leukemic cells selected for resistance to VM-26. Biochemistry 27:8861–8869CrossRefPubMed
7.
Zurück zum Zitat Frankfurt O, Rosen ST (2004) Mechanisms of glucocorticoid-induced apoptosis in hematologic malignancies: updates. Curr Opin Oncol 16:553–563CrossRefPubMed Frankfurt O, Rosen ST (2004) Mechanisms of glucocorticoid-induced apoptosis in hematologic malignancies: updates. Curr Opin Oncol 16:553–563CrossRefPubMed
8.
Zurück zum Zitat Gertz MA, Garton JP, Greipp PR, Witzig TE, Kyle RA (1995) A phase II study of high-dose methylprednisolone in refractory or relapsed multiple myeloma. Leukemia 9:2115–2118PubMed Gertz MA, Garton JP, Greipp PR, Witzig TE, Kyle RA (1995) A phase II study of high-dose methylprednisolone in refractory or relapsed multiple myeloma. Leukemia 9:2115–2118PubMed
9.
Zurück zum Zitat Gomi M, Moriwaki K, Katagiri S, Kurata Y, Thompson EB (1990) Glucocorticoid effects on myeloma cells in culture: correlation of growth inhibition with induction of glucocorticoid receptor messenger RNA. Cancer Res 50:1873–1878PubMed Gomi M, Moriwaki K, Katagiri S, Kurata Y, Thompson EB (1990) Glucocorticoid effects on myeloma cells in culture: correlation of growth inhibition with induction of glucocorticoid receptor messenger RNA. Cancer Res 50:1873–1878PubMed
10.
Zurück zum Zitat Gottesman MM, Fojo T, Bates SE (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2:48–58CrossRefPubMed Gottesman MM, Fojo T, Bates SE (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2:48–58CrossRefPubMed
11.
Zurück zum Zitat Hart CP (2005) Finding the target after screening the phenotype. Drug Discov Today 10:513–519CrossRefPubMed Hart CP (2005) Finding the target after screening the phenotype. Drug Discov Today 10:513–519CrossRefPubMed
12.
Zurück zum Zitat Hazlehurst LA, Foley NE, Gleason-Guzman MC, Hacker MP, Cress AE, Greenberger LW, De Jong MC, Dalton WS (1999) Multiple mechanisms confer drug resistance to mitoxantrone in the human 8226 myeloma cell line. Cancer Res 59:1021–1028PubMed Hazlehurst LA, Foley NE, Gleason-Guzman MC, Hacker MP, Cress AE, Greenberger LW, De Jong MC, Dalton WS (1999) Multiple mechanisms confer drug resistance to mitoxantrone in the human 8226 myeloma cell line. Cancer Res 59:1021–1028PubMed
13.
Zurück zum Zitat Hazlehurst LA, Enkemann SA, Beam CA, Argilagos RF, Painter J, Shain KH, Saporta S, Boulware D, Moscinski L, Alsina M, Dalton WS (2003) Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model. Cancer Res 63:7900–7906PubMed Hazlehurst LA, Enkemann SA, Beam CA, Argilagos RF, Painter J, Shain KH, Saporta S, Boulware D, Moscinski L, Alsina M, Dalton WS (2003) Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model. Cancer Res 63:7900–7906PubMed
14.
Zurück zum Zitat Herrlich P (2001) Cross-talk between glucocorticoid receptor and AP-1. Oncogene 20:2465–2475CrossRefPubMed Herrlich P (2001) Cross-talk between glucocorticoid receptor and AP-1. Oncogene 20:2465–2475CrossRefPubMed
15.
Zurück zum Zitat Kelley BP, Lunn MR, Root DE, Flaherty SP, Martino AM, Stockwell BR (2004) A flexible data analysis tool for chemical genetic screens. Chem Biol 11:1495–1503CrossRefPubMed Kelley BP, Lunn MR, Root DE, Flaherty SP, Martino AM, Stockwell BR (2004) A flexible data analysis tool for chemical genetic screens. Chem Biol 11:1495–1503CrossRefPubMed
16.
Zurück zum Zitat Kumar R, Thompson EB (2005) Gene regulation by the glucocorticoid receptor: structure:function relationship. J Steroid Biochem Mol Biol 94:383–394CrossRefPubMed Kumar R, Thompson EB (2005) Gene regulation by the glucocorticoid receptor: structure:function relationship. J Steroid Biochem Mol Biol 94:383–394CrossRefPubMed
17.
Zurück zum Zitat Larsson R, Nygren P, Ekberg M, Slater L (1990) Chemotherapeutic drug sensitivity testing of human leukemia cells in vitro using a semiautomated fluorometric assay. Leukemia 4:567–571PubMed Larsson R, Nygren P, Ekberg M, Slater L (1990) Chemotherapeutic drug sensitivity testing of human leukemia cells in vitro using a semiautomated fluorometric assay. Leukemia 4:567–571PubMed
18.
Zurück zum Zitat Longley DB, Johnston PG (2005) Molecular mechanisms of drug resistance. J Pathol 205:275–292CrossRefPubMed Longley DB, Johnston PG (2005) Molecular mechanisms of drug resistance. J Pathol 205:275–292CrossRefPubMed
19.
Zurück zum Zitat Mao Y, Yu C, Hsieh TS, Nitiss JL, Liu AA, Wang H, Liu LF (1999) Mutations of human topoisomerase II alpha affecting multidrug resistance and sensitivity. Biochemistry 38:10793–10800CrossRefPubMed Mao Y, Yu C, Hsieh TS, Nitiss JL, Liu AA, Wang H, Liu LF (1999) Mutations of human topoisomerase II alpha affecting multidrug resistance and sensitivity. Biochemistry 38:10793–10800CrossRefPubMed
20.
Zurück zum Zitat Mirski SE, Gerlach JH, Cole SP (1987) Multidrug resistance in a human small cell lung cancer cell line selected in adriamycin. Cancer Res 47:2594–2598PubMed Mirski SE, Gerlach JH, Cole SP (1987) Multidrug resistance in a human small cell lung cancer cell line selected in adriamycin. Cancer Res 47:2594–2598PubMed
21.
Zurück zum Zitat Naumann U, Durka S, Weller M (1998) Dexamethasone-mediated protection from drug cytotoxicity: association with p21WAF1/CIP1 protein accumulation? Oncogene 17:1567–1575CrossRefPubMed Naumann U, Durka S, Weller M (1998) Dexamethasone-mediated protection from drug cytotoxicity: association with p21WAF1/CIP1 protein accumulation? Oncogene 17:1567–1575CrossRefPubMed
23.
Zurück zum Zitat Peeters BW, Tonnaer JA, Groen MB, Broekkamp CL, van der Voort HA, Schoonen WG, Smets RJ, Vanderheyden PM, Gebhard R, Ruigt GS (2004) Glucocorticoid receptor antagonists: new tools to investigate disorders characterized by cortisol hypersecretion. Stress 7:233–241PubMedCrossRef Peeters BW, Tonnaer JA, Groen MB, Broekkamp CL, van der Voort HA, Schoonen WG, Smets RJ, Vanderheyden PM, Gebhard R, Ruigt GS (2004) Glucocorticoid receptor antagonists: new tools to investigate disorders characterized by cortisol hypersecretion. Stress 7:233–241PubMedCrossRef
24.
Zurück zum Zitat Pommier Y, Sordet O, Antony S, Hayward RL, Kohn KW (2004) Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene 23:2934–2949CrossRefPubMed Pommier Y, Sordet O, Antony S, Hayward RL, Kohn KW (2004) Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene 23:2934–2949CrossRefPubMed
25.
Zurück zum Zitat Redmond DE Jr, Zhao JL, Randall JD, Eklund AC, Eusebi LO, Roth RH, Gullans SR, Jensen RV (2003) Spatiotemporal patterns of gene expression during fetal monkey brain development. Brain Res Dev Brain Res 146:99–106CrossRefPubMed Redmond DE Jr, Zhao JL, Randall JD, Eklund AC, Eusebi LO, Roth RH, Gullans SR, Jensen RV (2003) Spatiotemporal patterns of gene expression during fetal monkey brain development. Brain Res Dev Brain Res 146:99–106CrossRefPubMed
26.
Zurück zum Zitat Rickardson L, Fryknas M, Dhar S, Lovborg H, Gullbo J, Rydaker M, Nygren P, Gustafsson MG, Larsson R, Isaksson A (2005) Identification of molecular mechanisms for cellular drug resistance by combining drug activity and gene expression profiles. Br J Cancer 93:483–492CrossRefPubMed Rickardson L, Fryknas M, Dhar S, Lovborg H, Gullbo J, Rydaker M, Nygren P, Gustafsson MG, Larsson R, Isaksson A (2005) Identification of molecular mechanisms for cellular drug resistance by combining drug activity and gene expression profiles. Br J Cancer 93:483–492CrossRefPubMed
27.
Zurück zum Zitat Root DE, Flaherty SP, Kelley BP, Stockwell BR (2003) Biological mechanism profiling using an annotated compound library. Chem Biol 10:881–892CrossRefPubMed Root DE, Flaherty SP, Kelley BP, Stockwell BR (2003) Biological mechanism profiling using an annotated compound library. Chem Biol 10:881–892CrossRefPubMed
28.
Zurück zum Zitat Scherf U, Ross DT, Waltham M, Smith LH, Lee JK, Tanabe L, Kohn KW, Reinhold WC, Myers TG, Andrews DT, Scudiero DA, Eisen MB, Sausville EA, Pommier Y, Botstein D, Brown PO, Weinstein JN (2000) A gene expression database for the molecular pharmacology of cancer. Nat Genet 24:236–244CrossRefPubMed Scherf U, Ross DT, Waltham M, Smith LH, Lee JK, Tanabe L, Kohn KW, Reinhold WC, Myers TG, Andrews DT, Scudiero DA, Eisen MB, Sausville EA, Pommier Y, Botstein D, Brown PO, Weinstein JN (2000) A gene expression database for the molecular pharmacology of cancer. Nat Genet 24:236–244CrossRefPubMed
29.
Zurück zum Zitat Slovak ML, Ho JP, Bhardwaj G, Kurz EU, Deeley RG, Cole SP (1993) Localization of a novel multidrug resistance-associated gene in the HT1080/DR4 and H69AR human tumor cell lines. Cancer Res 53:3221–3225PubMed Slovak ML, Ho JP, Bhardwaj G, Kurz EU, Deeley RG, Cole SP (1993) Localization of a novel multidrug resistance-associated gene in the HT1080/DR4 and H69AR human tumor cell lines. Cancer Res 53:3221–3225PubMed
30.
Zurück zum Zitat Subramaniam N, Treuter E, Okret S (1999) Receptor interacting protein RIP140 inhibits both positive and negative gene regulation by glucocorticoids. J Biol Chem 274:18121–18127CrossRefPubMed Subramaniam N, Treuter E, Okret S (1999) Receptor interacting protein RIP140 inhibits both positive and negative gene regulation by glucocorticoids. J Biol Chem 274:18121–18127CrossRefPubMed
31.
Zurück zum Zitat Williams SP, Sigler PB (1998) Atomic structure of progesterone complexed with its receptor. Nature 393:392–396CrossRefPubMed Williams SP, Sigler PB (1998) Atomic structure of progesterone complexed with its receptor. Nature 393:392–396CrossRefPubMed
Metadaten
Titel
Screening of an annotated compound library for drug activity in a resistant myeloma cell line
verfasst von
Linda Rickardson
Mårten Fryknäs
Caroline Haglund
Henrik Lövborg
Peter Nygren
Mats G. Gustafsson
Anders Isaksson
Rolf Larsson
Publikationsdatum
01.12.2006
Verlag
Springer-Verlag
Erschienen in
Cancer Chemotherapy and Pharmacology / Ausgabe 6/2006
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-006-0216-7

Weitere Artikel der Ausgabe 6/2006

Cancer Chemotherapy and Pharmacology 6/2006 Zur Ausgabe

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

26.05.2024 Mammakarzinom Nachrichten

Frauen, die zum Zeitpunkt der Brustkrebsdiagnose eine hohe mammografische Brustdichte aufweisen, haben ein erhöhtes Risiko für ein baldiges Rezidiv, legen neue Daten nahe.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.